Citigroup Issues Positive Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its target price hoisted by investment analysts at Citigroup from $16.00 to $22.00 in a research report issued on Tuesday, Benzinga reports. The firm presently has a “sell” rating on the life sciences company’s stock. Citigroup’s price target points to a potential downside of 9.28% from the stock’s current price.

A number of other research analysts also recently issued reports on the company. Truist Financial dropped their price objective on Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday, October 14th. BTIG Research upgraded Integra LifeSciences from a “sell” rating to a “neutral” rating in a report on Monday, October 7th. Morgan Stanley lifted their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research note on Monday, July 15th. JMP Securities cut their target price on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating on the stock in a research note on Tuesday, July 30th. Finally, Bank of America reduced their price target on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a report on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $27.25.

Integra LifeSciences Trading Up 0.5 %

Shares of Integra LifeSciences stock traded up $0.13 during midday trading on Tuesday, reaching $24.25. The company had a trading volume of 253,489 shares, compared to its average volume of 1,094,781. The firm has a market cap of $1.88 billion, a PE ratio of 84.14, a P/E/G ratio of 0.66 and a beta of 1.08. The stock has a fifty day moving average price of $18.62 and a 200 day moving average price of $24.46. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences has a fifty-two week low of $16.81 and a fifty-two week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.02. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. The firm had revenue of $380.80 million for the quarter, compared to the consensus estimate of $375.81 million. During the same quarter in the previous year, the company earned $0.76 EPS. The company’s revenue for the quarter was down .4% on a year-over-year basis. On average, equities analysts anticipate that Integra LifeSciences will post 2.45 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new position in Integra LifeSciences during the 3rd quarter valued at about $960,000. Versor Investments LP bought a new position in shares of Integra LifeSciences in the third quarter valued at approximately $612,000. Olstein Capital Management L.P. boosted its position in shares of Integra LifeSciences by 37.2% during the third quarter. Olstein Capital Management L.P. now owns 155,000 shares of the life sciences company’s stock valued at $2,816,000 after buying an additional 42,000 shares during the last quarter. Principal Financial Group Inc. grew its holdings in Integra LifeSciences by 18.7% during the third quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company’s stock worth $7,294,000 after buying an additional 63,266 shares in the last quarter. Finally, New York State Teachers Retirement System raised its position in Integra LifeSciences by 3.0% in the 3rd quarter. New York State Teachers Retirement System now owns 90,098 shares of the life sciences company’s stock valued at $1,637,000 after buying an additional 2,616 shares during the last quarter. 84.78% of the stock is owned by institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.